Survival of patients with recurrent glioblastoma multiforme treated with local carmustine wafer (Gliadel) in relation to the methylation of methylguanin-DNA-methyltransferase (MGMT) promotor

Trial Profile

Survival of patients with recurrent glioblastoma multiforme treated with local carmustine wafer (Gliadel) in relation to the methylation of methylguanin-DNA-methyltransferase (MGMT) promotor

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Carmustine polifeprosan 20 wafer (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 13 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top